Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARES-310: Camrelizumab + Rivoceranib vs Sorafenib in Advanced HCC
NCT03764293Phase 3Completed
- Sponsor
- Hengrui
- Start
- Jun 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 13
01
Overview
A Phase 3 trial of camrelizumab, Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Hengrui. Started Jun 2019; status: completed.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03764293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03764293.